Efficacy and safety of Oxalobacter formigenes to reduce urinary oxalate in primary hyperoxaluria
Bernd Höppe(University of Bonn), Dawn S. Milliner(Mayo Clinic), Georges Deschênes(Hôpital Robert-Debré), Robert J. Unwin(The Royal Free Hospital), Markus J. Kemper(University of Zurich), Sally A. Hulton(Birmingham Children's Hospital), Patrick Niaudet(Hôpital Necker-Enfants Malades), Pierre Cochat(Karolinska Institutet), Jaap W. Groothoff(Emma Kinderziekenhuis)
Cited by 144
Related Papers
The centrosomal protein nephrocystin-6 is mutated in Joubert syndrome and activates transcription factor ATF4
|Nature Genetics|2006|572
Kidney Disease: Improving Global Outcomes guidelines on anaemia management in chronic kidney disease: a European Renal Best Practice position statement
|Nephrology Dialysis Transplantation|2013|472
History, epidemiology and regional diversities of urolithiasis
|Pediatric Nephrology|2008|460
The primary hyperoxalurias
|Kidney International|2009|373
Early angiotensin-converting enzyme inhibition in Alport syndrome delays renal failure and improves life expectancy
|Kidney International|2011|361